Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Survival patterns of stage IV liver cancers in the United States

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Mohammed Mousa

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

M. Mousa, A. Meshref, K. Alsabahy

Author affiliations

  • Faculty Of Medicine, Suez Canal University, 41111 - Ismailia/EG
More

Resources

Abstract 1328

Aim/Background

This study aimed at evaluation of relative survival rates of patients with stage IV liver cancers over the last decade in the United States: 2003-2012 using the Surveillance, Epidemiology, and End Results (SEER) Registry.

Methods

We used SEER*Stat Program to analyze 6-month and 12-month relative survival rates of 7252 American Joint Committee on Cancer (AJCC) Stage IV liver cancer cases by actuarial method. We compared relative survival rates among groups of patients categorized by sex, race, and age groups (≥60 and <60 years) using Z-test.

Results

There was a statistically significant increase in both 6 and12-month relative survival rates for adenocarcinomas (26.6 ± 0.6% and 13.5 ± 0.4%) in comparison to other epithelial (10.5 ± 1.9% and 5.9 ± 1.5%) and unspecified (10.5 ± 2.2% and 5.2 ± 1.7%) neoplasms (P < 0.001). We also found a significant increase in both 6 and 12-month relative survival rates for age group <60 years (27.1 ± 0.8% and 14 ± 0.6%) in comparison to age group ≥60 years (24 ± 0.7% and 12 ± 0.6%, P < 0.001). Our study results didn't show a significant difference in survival when the cases were categorized according to sex or race.

Conclusions

Tumor's histology and patient's age can affect the relative survival rates in stage IV liver cancer cases while sex and race seem to have no effect on relative survival in such cases. These findings can help in designing better disease prognostic counselling and surveillance programs.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings